Health Data Specialists, “HeaDS” is a full-service European Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with particular expertise in hemato-oncology studies. We provide the complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, we provide strategic oncology drug development consulting and expert advice as we understand the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market.
HeaDS has invested considerably in its infrastructure. We strive to employ top professionals and develop premier software to meet and exceed our client needs. At HeaDS we believe that true passion and devotion are key to be able to excel in what you do.
HeaDS was founded in 2010 in Athens, Greece. Fueled by tireless work and true passion, HeaDS has grown exponentially to an international CRO managing clinical trials of various sizes and complexities. We have grown wiser over time, year by year adding experience on our backs, yet our passion burns unchanged all throughout.
OUR CLINICAL RESEARCH
We invest heavily in our people and in-house technology. This way we can guarantee true ﬂexibility, customization and quality in our work.
Hemato-Oncology is the core of our global clinical program. As such, disease area expertise across all functions is a top priority.
Our engineers and quantitative scientists will back any decision making with concrete data. No leap of faith required!
VP, Regulatory and
HeaDS Vice President, representing all regulatory and clinical affairs and being responsible for key client management
Clinical Operations Director
Leads HeaDS clinical operations activities across the whole clinical program
Biometrics Program Manager
Drives the whole HeaDS biometrics program, including data management, biostatistics and IT
Leads PV program across all HeaDS clinical studies
A Phase 3 pivotal study comparing Daratumumab-Pomalidomide-Dexamethasone vs Pomalidomide-Dexamethasone in relapsed refractory multiple myeloma patients previously treated with lenalidomide and a proteasome inhibitor (at least one prior line).
A Phase 2 study of daratumumab monotherapy in newly diagnosed patients with Stage 3B light chain (AL) amyloidosis.
A Phase 2 study of Daratumumab combined with Bortezomib, Cyclophosphamide and dexamethasone in Multiple Myeloma patients with Extramedullary Disease.